Short-term Efficacy Of Calcium Fructoborate On Subjects With Knee Discomfort: A Comparative, Double-blind, Placebo-controlled Clinical Study
Notes for this study:
||WOMAC. Mean and SD. Placebo: before 52.70±12.66, after 51.03±10.36. Boron: before 53.57±13.69, after 38.17±10.11.
|Number of Subjects
In a randomized, double-blind, placebo-controlled trial, 60 participants experiencing knee discomfort were allocated to take 220 mg of calcium fructoborate (6 mg of boron) or placebo daily for 14 days.
Knee discomfort on the WOMAC and MPQ questionnaires was the primary outcome, and there was a considerable reduction in both in the boron groups, and no change in the control group, the difference being statistically significant.